Should you sell your Cellectar Biosciences stock?

Roth Capital Markets analyst Jonathan Aschoff lowered his price target on Cellectar Biosciences (Cellectar Biosciences Stock Quote, Chart, News, Analysts, Financials NASDAQ:CLRB) to $14.00 from $18.00 while maintaining a “Buy” rating in a March 4 earnings update.

Cellectar ended Q4 2025 with $13.2-million in cash, providing runway into Q3 2026.

Aschoff said the company and the FDA have defined a regulatory path for iopofosine I 131 in relapsed/refractory Waldenström’s macroglobulinemia (WM), including potential Accelerated Approval based on major response rate (MRR), followed by full approval using progression-free survival (PFS). The company intends to out-license the drug to a partner to fund and conduct the pivotal Phase 3 trial, estimated to cost approximately $40.0-million and enroll about 200 patients.

In Europe, the EMA indicated Cellectar may seek Conditional Marketing Authorization (CMA) for iopofosine in post-BTK inhibitor WM using existing data. A submission is expected in Q3 2026, potentially supporting EU approval in the second half of 2027. Iopofosine already holds PRIME designation in WM.

The CLOVER trial demonstrated an 83.6% overall response rate and a 58.2% major response rate in heavily pretreated patients. Aschoff noted that evaluating the drug earlier in the treatment paradigm could expand the addressable U.S. market.

Beyond WM, Cellectar has initiated a Phase 1b/2a study of CLR 125 in relapsed/refractory triple-negative breast cancer, with initial data expected in mid-2026. A Phase 1a study of CLR 225 in pancreatic cancer is also planned.

Model adjustments reflecting timing and partnership assumptions resulted in the lower $14.00 target price.

-30-